Trials / Completed
CompletedNCT00350155
Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel
A 16-Day, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial Comparing Lumiracoxib 100mg o.d. With Naproxen 500 mg b.i.d. Plus Omeprazole 20mg o.d. and Placebo in Healthy Volunteers to Investigate on the Safety and Tolerability of Lumiracoxib in the Small Bowel.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is designed to investigate the potential differences in GI safety and tolerability in the small bowel between lumiracoxib, conventional non-selective NSAID (naproxen) with a proton pump inhibitor (omeprazole), or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lumiracoxib |
Timeline
- Start date
- 2006-05-01
- First posted
- 2006-07-10
- Last updated
- 2007-12-13
Locations
2 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00350155. Inclusion in this directory is not an endorsement.